| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, ... The Journal of clinical investigation 118 (9), 3065-3074, 2008 | 1666 | 2008 |
| Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate BS Carver, J Tran, A Gopalan, Z Chen, S Shaikh, A Carracedo, A Alimonti, ... Nature genetics 41 (5), 619-624, 2009 | 778 | 2009 |
| Subtle variations in Pten dose determine cancer susceptibility A Alimonti, A Carracedo, JG Clohessy, LC Trotman, C Nardella, A Egia, ... Nature genetics 42 (5), 454-458, 2010 | 679 | 2010 |
| Pro-senescence therapy for cancer treatment C Nardella, JG Clohessy, A Alimonti, PP Pandolfi Nature Reviews Cancer 11 (7), 503-511, 2011 | 507 | 2011 |
| Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence HK Lin, Z Chen, G Wang, C Nardella, SW Lee, CH Chan, WL Yang, ... Nature 464 (7287), 374-379, 2010 | 473 | 2010 |
| Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ... Cancer discovery 2 (11), 1048-1063, 2012 | 456 | 2012 |
| A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis A Alimonti, C Nardella, Z Chen, JG Clohessy, A Carracedo, LC Trotman, ... The Journal of clinical investigation 120 (3), 681-693, 2010 | 414 | 2010 |
| A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer A Lunardi, U Ala, MT Epping, L Salmena, JG Clohessy, KA Webster, ... Nature genetics 45 (7), 747-755, 2013 | 172 | 2013 |
| Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion G Wang, A Lunardi, J Zhang, Z Chen, U Ala, KA Webster, Y Tay, ... Nature genetics 45 (7), 739-746, 2013 | 148 | 2013 |
| The APL paradigm and the “co-clinical trial” project C Nardella, A Lunardi, A Patnaik, LC Cantley, PP Pandolfi Cancer discovery 1 (2), 108-116, 2011 | 139 | 2011 |
| Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events C Nardella, Z Chen, L Salmena, A Carracedo, A Alimonti, A Egia, ... Genes & development 22 (16), 2172-2177, 2008 | 139 | 2008 |
| ETS rearrangements and prostate cancer initiation BS Carver, J Tran, Z Chen, A Carracedo-Perez, A Alimonti, C Nardella, ... Nature 457 (7231), E1-E1, 2009 | 130 | 2009 |
| Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein M Pallaoro, A Lahm, G Biasiol, M Brunetti, C Nardella, L Orsatti, F Bonelli, ... Journal of virology 75 (20), 9939-9946, 2001 | 120 | 2001 |
| Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells Y Nadir, B Brenner, S Gingis-Velitski, F Levy-Adam, N Ilan, E Zcharia, ... Thrombosis and haemostasis 99 (01), 133-141, 2008 | 110 | 2008 |
| Mechanism of activation of human heparanase investigated by protein engineering C Nardella, A Lahm, M Pallaoro, M Brunetti, A Vannini, C Steinkühler Biochemistry 43 (7), 1862-1873, 2004 | 97 | 2004 |
| Vulnerabilities of PTEN–TP53-Deficient Prostate Cancers to Compound PARP–PI3K Inhibition E González-Billalabeitia, N Seitzer, SJ Song, MS Song, A Patnaik, XS Liu, ... Cancer discovery 4 (8), 896-904, 2014 | 96 | 2014 |
| Differential requirement of mTOR in postmitotic tissues and tumorigenesis C Nardella, A Carracedo, A Alimonti, RM Hobbs, JG Clohessy, Z Chen, ... Science signaling 2 (55), ra2-ra2, 2009 | 92 | 2009 |
| MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells D Stroopinsky, J Rosenblatt, K Ito, H Mills, L Yin, H Rajabi, B Vasir, T Kufe, ... Cancer research 73 (17), 5569-5579, 2013 | 60 | 2013 |
| Circulating RNAs in prostate cancer patients V Mugoni, Y Ciani, C Nardella, F Demichelis Cancer letters 524, 57-69, 2022 | 52 | 2022 |
| Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012; 2: 1048–1063. doi: 10.1158/2159-8290 A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ... CD-11-0336.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 46 | |
